Antagonism of cannabinoid receptor 2 pathway suppresses IL-6-induced immunoglobulin IgM secretion

[1] Howlett AC(2002)International Union of Pharmacology. XXVII. Classification of cannabinoid receptors Pharmacol Rev 54 161-202

[2] Barth F(2006)Targeting the CB2 receptor for immune modulation Expert Opin Ther Targets 10 653-663

[3] Bonner TI(1995)Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations Eur J Biochem 232 54-61

[4] Cabral G(2007)Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials Lancet 370 1706-1713

[5] Casellas P(2006)Design, synthesis, and biological evaluation of new 1,8-naphthyridin-4(1H)-on-3-carboxamide and quinolin-4(1H)-on-3-carboxamide derivatives as CB2 selective agonists J Med Chem 49 5947-5957

[6] Devane WA(2008)Cannabinoids for cancer treatment: progress and promise Cancer Res 68 339-342

[7] Felder CC(2007)Anandamide and Delta9-tetrahydrocannabinol directly inhibit cells of the immune system via CB2 receptors J Neuroimmunol 189 17-22

[8] Herkenham M(2005)Cannabinoid-based drugs as anti-inflammatory therapeutics Nat Rev Immunol 5 400-411

[9] Mackie K(2007)The cannabinoid CB2 receptor as a target for inflammation-dependent neurodegeneration Curr Neuropharmacol 5 73-80

[10] Martin BR(2011)Mechanisms of osteoclastogenesis inhibition by a novel class of biphenyl-type cannabinoid CB(2) receptor inverse agonists Chem Biol 18 1053-1064

[1] Howlett AC(2002)International Union of Pharmacology. XXVII. Classification of cannabinoid receptors Pharmacol Rev 54 161-202

[2] Barth F(2006)Targeting the CB2 receptor for immune modulation Expert Opin Ther Targets 10 653-663

[3] Bonner TI(1995)Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations Eur J Biochem 232 54-61

[4] Cabral G(2007)Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials Lancet 370 1706-1713

[5] Casellas P(2006)Design, synthesis, and biological evaluation of new 1,8-naphthyridin-4(1H)-on-3-carboxamide and quinolin-4(1H)-on-3-carboxamide derivatives as CB2 selective agonists J Med Chem 49 5947-5957

[6] Devane WA(2008)Cannabinoids for cancer treatment: progress and promise Cancer Res 68 339-342

[7] Felder CC(2007)Anandamide and Delta9-tetrahydrocannabinol directly inhibit cells of the immune system via CB2 receptors J Neuroimmunol 189 17-22

[8] Herkenham M(2005)Cannabinoid-based drugs as anti-inflammatory therapeutics Nat Rev Immunol 5 400-411

[9] Mackie K(2007)The cannabinoid CB2 receptor as a target for inflammation-dependent neurodegeneration Curr Neuropharmacol 5 73-80

[10] Martin BR(2011)Mechanisms of osteoclastogenesis inhibition by a novel class of biphenyl-type cannabinoid CB(2) receptor inverse agonists Chem Biol 18 1053-1064